OXYCODONE HYDROCHLORIDE (oxycodone hydrochloride) by Bayer is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 2010.
Drug data last refreshed 14h ago · AI intelligence enriched 2d ago
Oxycodone hydrochloride is a full mu-opioid receptor agonist oral solution indicated for pain management. It works by binding to opioid receptors in the central nervous system to produce analgesia, with no ceiling effect on pain relief. The drug is used across various pain conditions where opioid therapy is appropriate.
As LOE approaches, the brand team will shift focus from growth maintenance to lifecycle extension strategies and line extensions, with potential headcount consolidation around regulatory and medical affairs support.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Worked on OXYCODONE HYDROCHLORIDE at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on oxycodone hydrochloride during its LOE-approaching phase offers exposure to brand defense and lifecycle management strategies rather than launch dynamics. Roles emphasize regulatory navigation, payer management, and market segmentation as generic competition intensifies.